a phase ii study of daratumumab and pomalidomide in previously treated patients with al amyloidosis
Published 2 months ago • 87 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
1:20
phase ii study investigating the efficacy of daratumumab in patients with stage 3b al amyloidosis
-
5:07
daratumumab in the management of al amyloidosis
-
1:55
factors predicting outcomes in patients with al amyloidosis treated with daratumumab
-
0:44
outcomes of patients with al amyloidosis after failure of daratumumab-based therapy
-
2:41
optimizing the use of daratumumab in al amyloidosis
-
1:04
emn 27: phase ii study of belantamab mafodotin in patients with r/r al amyloidosis
-
1:06
daratumumab and carfilzomib for al amyloid neuropathy
-
4:30
andromeda: daratumumab for al amyloidosis
-
2:46
single use daratumumab for al amyloidosis
-
1:03
real-world management of patients with al amyloidosis
-
5:23
dual antibody therapy in patients with systemic al amyloidosis and cardiac involvement
-
1:45
real-world data in guiding amyloidosis treatment
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:21
insights into the management of systemic al amyloidosis
-
3:23
novel agents and clinical trials emerging for the treatment of al amyloidosis
-
2:56
early vs. deferred transplantation in al amyloidosis
-
2:49
highlights in al amyloidosis from ash 2022: emn22, emn27 & predictors of hematologic cr
-
3:15
goal of therapy in al amyloidosis: what predicts the best outcome?
-
5:16
the evolution of al amyloidosis therapy